Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762)

Journal of Clinical Oncology

Volumn 24, Issue 12, 2006, Pages 1846-1851

  Lichtman, Stuart M ^b   Hollis, Donna ^b   Miller, Antonius A ^b   Rosner, Gary L ^b   Rhoades, Chris A ^b   Lester, Eric P ^b   Millard, Frederick ^b   Byrd, John ^b   Cullinan, Stephen A ^b   Rosen, D Marc ^b   Parise, Robert A ^b   Ratain, Mark J ^b   Egorin, Merrill J ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; PACLITAXEL; RANITIDINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; AGING; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; ESOPHAGUS CANCER; FEMALE; HEAD AND NECK CANCER; HOSPITALIZATION; HUMAN; LARYNX CARCINOMA; LEUKEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; STOMACH CANCER; TOXICITY; UNSPECIFIED SIDE EFFECT; AGE; CLINICAL TRIAL; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; PROSPECTIVE STUDY;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASMS; PACLITAXEL; PROSPECTIVE STUDIES;

EID: 33646366957     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.9289     Document Type: Article

References (37)

1. Yancik R: Cancer burden in the aged: An epidemiologic and demographic overview. Cancer 80:1273-1283, 1997
2. Yee KW, Pater JL, Pho L, et al: Enrollment of older patients in cancer treatment trials in Canada: Why is age a barrier? J Clin Oncol 21:1618-1623, 2003
3. Hutchins LF, Unger JM, Crowley JJ, et al: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341:2061-2067, 1999
4. Begg CB, Carbone PP: Clinical trials and drug toxicity in the elderly: The experience of the Eastern Cooperative Oncology Group. Cancer 52:1986-1992, 1983
5. Begg CB, Elson PJ, Carbone PP: A study of excess hematologic toxicity in elderly patients treated on cancer chemotherapy protocols, in Yancik R, Yates JW (eds): Cancer in the Elderly: A Approach to Early Detection and Treatment. New York, NY, Springer, 1989, pp 149-163
6. Tumer N, Scarpace PJ, Lowenthal DT: Geriatric pharmacology: Basic and clinical considerations. Annu Rev Pharmacol Toxicol 32:271-302, 1992
7. Shock NW, Watkin DM, Yiengst BS, et al: Age differences in water content of the body as related to basal oxygen consumption in males. J Gerontol 18:1-8, 1963
8. Forbes GB, Reina JC: Adult lean body mass declines with age: Some longitudinal observations. Metabolism 19:653-663, 1978
9. Adelman LS, Liebman J: Anatomy of body water and electrolytes. Am J Med 27:256-277, 1959
10. Lindeman RD, Tobin J, Shock NW: Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 33:278-285, 1985
11. Sotaniemi EA, Arranto AJ, Pelkonen O, et al: Age and cytochrome P450-linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 61:331-339, 1997
12. Satariano WA, Ragland DA: The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120:104-110, 1994
13. Repetto L, Comandini D, Mammoliti S: Life expectancy, comorbidity and quality of life: The treatment equation in the older cancer patients. Crit Rev Oncol Hematol 37:147-152, 2001
14. Egorin MJ: Cancer pharmacology in the elderly. Semin Oncol 20:43-49, 1993
15. Argiris A, Li Y, Murphy BA, et al: Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. J Clin Oncol 22:262-268, 2004
16. Del Mastro L, Perrone F, Repetto L, et al: Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: A phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). Ann Oncol 16:253-258, 2005
17. Repetto L, Comandini D, Mammoliti S, et al: Weekly paclitaxel in elderly patients with advanced breast cancer: A dose-finding study. Drugs R D 5:11-15, 2004
18. Fidias P, Supko JG, Martins R, et al: A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res 7:3942-3949, 2001
19. Perez EA, Vogel CL, Irwin DH, et al: Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19:4216-4223, 2001
20. 2 as a 3 hour infusion. Clin Drug Invest 13:344-353, 1995
21. Glantz MJ, Choy H, Kearns CM, Mills PC, et al: Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. J Natl Cancer Inst 87:1077-1081, 1995
22. Jamis-Dow CA, Klecker RW, Sarosy G, et al: Steady-stage plasma concentrations and effects of taxol at 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. Cancer Chemother Pharmacol 33:48-52, 1993
23. Kearns C, Gianni L, Vigano L, et al: Validation of paclitaxel limited sampling strategies. Proc Am Soc Clin Oncol 16, 1997 (abstr 720)
24. Landis RJ, Heyman ER, Koch GG: Average partial association in three-way contingency tables: A review and discussion of alternative tests. Int Stat Rev 46:237-254, 1978
25. Agresti A: Categorical Data Analysis (ed 2). New York, NY, Wiley-Interscience, 2002
26. Lehmann EL: Nonparametrics: Statistical methods based on ranks. San Francisco, CA, Holden-Day Inc, 1975
27. Bicher A, Sarosy G, Kohn E, et al: Age does not influence Taxol dose intensity in recurrent carcinoma of the ovary. Cancer 71:594-600, 1993 (suppl 2)
28. Smorenburg CH, ten Tije AJ, Verweij J, et al: Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. Eur J Cancer 39:196-202, 2003
29. Tornio A, Pasanen MK, Laitila J, Neuvonen PJ, Backman JT: Comparison of 3-Hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. Basic Clin Pharmacol Toxicol 97:104-108, 2005
30. Gianni L, Kearns CM, Giani A, et al: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13:180-190, 1995
31. Gelderblom H, Mross K, ten Tije AJ, et al: Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J Clin Oncol 20:574-581, 2002
32. Perez EA, Vogel CL, Irwin DH, et al: Weekly paclitaxel in women age 65 and above with metastatic breast cancer. Breast Cancer Res Treat 73:85-88, 2002
33. Wildiers H, Paridaens R: Taxanes in elderly breast cancer patients. Cancer Treat Rev 30:333-342, 2004
34. Fried LP, Tangen CM, Walston J, et al: Frailty in older adults: Evidence for a phenotype. J Gerontol Biol Sci Med Sci 56:M146-M156, 2001
35. Venook AP, Egorin MJ, Rosner GL, et al: Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol 16:1811-1819, 1998
36. Venook AP, Egorin MJ, Rosner GL, et al: Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 18:2780-2787, 2000
37. Venook AP, Enders Klein C, Fleming G, et al: A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol 14:1783-1790, 2003